Novo Nordisk experienced its largest single-day drop in stock value after the company reported disappointing clinical trial results for its newly developed weight management drug. The announcement raised concerns among investors about the drug’s market potential, leading to a sharp decline in share price and significant sell-offs on trading platforms.